GlassScriptPhysician profile
Sanjeev Wasson
NPI 1285805036
$4,232.66
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,604 · 2020: $2,629.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $599.65 | 2019 | |
| Medtronic Vascular, INC. | $304.18 | 2019 | |
| Abbott Laboratories | $166.13 | 2019 | |
| Boston Scientific Corporation | $134.33 | 2019 | |
| Genzyme Corporation | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $87.66 | 2019-2020 | |
| Amgen INC. | $59.38 | 2019-2020 | |
| Pfizer INC. | $51.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $48.35 | 2019 | |
| Biosense Webster, INC. | $33.38 | 2019 | |
| Edwards Lifesciences Corporation | $24.51 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.94 | 2019 | |
| Amarin Pharma, INC. | $12.63 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Wasson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.